



## INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 1

ATTORNEY DOCKET	APPLICATION NO.
25352-0029	09/977,659 FEB 28 2002
APPLICANT(S)	
Prasad V.V.S.V. Manchem, et al	

FILING DATE GROUP

October 11, 2001

1824

### U.S. PATENT DOCUMENTS

* EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)
WJS	1	5,830,918	11/1998	Sportsman, et al.	514/648	
	2	5,851,988	12/1998	Sportsman, et al.	514/4	
	3	6,020,374	02/2000	Geier, et al.	514/553	
WJS	4	6,051,597	04/2000	Zhang, et al.	514/414	

### FOREIGN PATENT DOCUMENTS

* EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
WJS	5	99/51225	10/1999	WO	
	6	01/12591	02/2001	WO	
	7	00/71506	11/2000	WO	
	8	91/03226	03/1991	WO	

### OTHER DOCUMENTS

* EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
WJS	9	Carr et al., "Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance", <i>Lancet</i> , 352, 1881-1883 (1988).
	10	Carr et al., "A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance In patients receiving HIV protease inhibitors", <i>AIDS</i> , 12, F51-F58 (1988).
	11	Roth et al., "Development of Cervical Fat Pads Following Therapy With Human Immunodeficiency Virus Type 1 Protease Inhibitors", <i>Clin. J. Infect. Dis.</i> , 27, 65-67 (1998).
	12	Safrin et al., "Fat distribution and metabolic changes In patients with HIV infection", <i>AIDS</i> , 13, 2493-2505 (1999).
	13	Carr et al., "Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study", <i>Lancet</i> , 353, 2093-2099 (1999).
	14	Behrens et al., "Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors", <i>AIDS</i> , 13, F63-F70 (1999).
	15	Reaven, "Role of insulin resistance in human disease (Syndrome X): an expanded definition", <i>Annu. Rev. Med.</i> , 44, 121-131 (1993).
WJS	16	Murata et al., "The mechanism of insulin resistance caused by HIV protease inhibitor therapy", <i>J. Biol. Chem.</i> , 27, 20251-20254 (2000).

EXAMINER'S SIGNATURE

DATE CONSIDERED

11/26/02

\* EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

\* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).